Alembic Limited
ALEMBICLTD.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$25.49B
Close$
$-11.58
111.9% downside
Current Fair Value
111.9% downsideOvervalued by 111.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $25.49 Billion |
|---|---|
| Enterprise Value | $25.49 Billion |
| Dividend Yield | $2.40 (2.42%) |
| Earnings per Share | $12.36 |
| Beta | 0.64 |
| Outstanding Shares | 256,781,828 |
Return
| Return on Equity | 13.11% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 7.95 |
|---|---|
| PEG | 150.83 |
| Price to Sales | 10.82 |
| Price to Book Ratio | 1.02 |
| Enterprise Value to Revenue | 10.66 |
| Enterprise Value to EBIT | 18.25 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Alembic Limited
329 employees
CEO: Chirayu Amin Alembic Limited specializes in the production and commercialization of active pharmaceutical ingredients (APIs) derived from both fermentation and chemistry-based processes. The company conducts its business through two primary divisions...